Vaxart Secures Additional BARDA Funding, Announces Imminent COVID-19 Trial Data Amidst Proxy Contest
VXRT sits 92% above its 52-week low of $0.261.
Summary
Vaxart filed additional proxy materials, announcing a new $29 million BARDA funding release and an imminent data readout for its Phase 2b COVID-19 trial, while actively campaigning for its current board in an ongoing proxy contest.
Key Events · Corporate Governance and Compliance · VXRT
-
Increased BARDA Funding
Vaxart announced a modification to its BARDA contract, releasing an additional $29 million for its Phase 2b COVID-19 trial, bringing total funding to approximately $345 million.
-
Imminent Phase 2b Data Readout
The company expects to report 12-month safety and immunogenicity data from the 400-participant Sentinel Cohort of its BARDA-funded Phase 2b COVID-19 trial "in the coming weeks."
-
Active Proxy Contest
Vaxart is actively soliciting shareholder votes to re-elect its current board of directors, defending against a dissident shareholder group that holds 0.5% of outstanding shares.
-
Board's Defense Strategy
The filing highlights the current board's achievements, including extending the cash runway into Q2 2027 and securing a Dynavax partnership, while criticizing the dissident nominees' lack of relevant experience and credible alternative plans.
Analysis · VXRT · Life Sciences
This filing serves as additional definitive proxy material, where Vaxart's board defends its performance and urges shareholders to vote for its nominees. Crucially, it reveals a new BARDA contract modification, releasing an additional $29 million for the Phase 2b COVID-19 trial and confirming that 12-month data from the Sentinel Cohort will be reported "in the coming weeks." This update provides significant financial support and a near-term catalyst for the company's lead program, which is a key argument for the current board's effectiveness in the ongoing proxy contest.
At the time of this filing, VXRT was trading at $0.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $122.7M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.